⺣ - רҵ·ĵϷƽ̨

ǰλãҳ > ICH-Q9质量风险管理 - 百度文库

ICH-Q9质量风险管理 - 百度文库

  • 62 Ķ
  • 3
  • 2025/6/2 7:21:39

Quality Risk Management/չ

authorities, communication concerning quality risk management decisions might be effected through existing channels as specified in regulations and guidances.

չͨھߺԱ֮йطպͷչϢ֮κηչ̽׶νйͨ(ͼ 1 ĵ㻮߼ͷ)չ̵/ӦʵĹͨʹ浵(ͼ 1 ʵ߼ͷ)ͨпܰЩط磬ҩҵ硢ҵ뻼ߡһ˾ҵҩڲȡϢӦյĴԡʡʽʡԡɽԡơɼԻйط档ͨҪÿսܶСҵҩ֮䣬ͿӰչ߹ͨЩͨͨеĹ»ָ˵С 4.6 Risk Review

Risk management should be an ongoing part of the quality management process. A mechanism to review or monitor events should be implemented.

չӦеһв֡Ӧʵʩһ¼мصĻơ

The output/results of the risk management process should be reviewed to take into account new knowledge and experience. Once a quality risk management process has been initiated, that process should continue to be utilized for events that might impact the original quality risk management decision, whether these events are planned (e.g., results of product review, inspections, audits, change control) or unplanned (e.g., root cause from failure investigations, recall). The frequency of any review should be based upon the level of risk. Risk review might include reconsideration of risk acceptance decisions (section4.4).

Էչ/ӦDzµ֪ʶ;顣һʼijչ̣ùӦһֱӦڿӰʼչߵ¼Щ¼ѱƻ(Ʒ󡢼顢ơƽ)δƻ(ʧܵĸԭ򡢼顢ٻ)ƵӦȡڷˮƽܰԷսܾ¿(4.4 ) 5. RISK MANAGEMENT METHODOLOGY չѧ

Quality risk management supports a scientific and practical approach to decision-making. It provides documented, transparent and reproducible methods to accomplish steps of the quality risk management process based on current knowledge about assessing the probability, severity and sometimes detectability of the risk.

չֿ֧ѧʵʷоߡйڷոʣԺһЩ¼Ŀɼ֪ʶĻϣṩļģ͸ĺͿظķʵչIJ衣

Traditionally, risks to quality have been assessed and managed in a variety of informal ways (empirical and/ or internal procedures) based on, for example,

compilation of observations, trends and other information. Such approaches continue to provide useful information that might support topics such as handling of complaints, quality defects, deviations and allocation of resources.

룺̷

13

Quality Risk Management/չ

ͳϣķյ͹ǻڶַʽķʽ(ģ/ڲ)磬ܡƺϡ෽ṩõϢЩϢ֧紦ͶߡȱݡƫԴ䡣 Additionally, the pharmaceutical industry and regulators can assess and manage risk using recognized risk management tools and/ or internal procedures (e.g., standard operating procedures). Below is a non-exhaustive list of some of these tools (further details in Annex 1 and chapter 8):

⣬ҩҵҩʹùϵķչߣ/ڲ(磬׼)͹ա²Щߵһ꾡б(ϸڸ 1 ͵ 8 )

? Basic risk management facilitation methods (flowcharts, check sheets etc.); չ׷(ͼ˶Ե)

? Failure Mode Effects Analysis (FMEA); ģʽЧӦ(FMEA)

? Failure Mode, Effects and Criticality Analysis (FMECA); ģʽӰԷ(FMECA)

? Fault Tree Analysis (FTA); (FTA)

? Hazard Analysis and Critical Control Points (HACCP); ΣؼƵ(HACCP)

? Hazard Operability Analysis (HAZOP); ΣɲԷ(HAZOP) ? Preliminary Hazard Analysis (PHA); ԤΣշ(PHA) ? Risk ranking and filtering; ˣ ? Supporting statistical tools. ͳƹߡ

It might be appropriate to adapt these tools for use in specific areas pertaining to drug substance and drug (medicinal) product quality. Quality risk management methods and the supporting statistical tools can be used in combination (e.g., Probabilistic Risk Assessment). Combined use provides flexibility that can facilitate the application of quality risk management principles.

ԭҩҩ(ҽ)ƷضЩ߿ǡġչԼͳƹ߿ʹ(磬Է)ʹṩԣԿԴٽչԭӦá

The degree of rigor and formality of quality risk management should reflect available knowledge and be commensurate with the complexity and/ or criticality of the issue to be addressed.

չϸ̶ʽӦӳõ֪ʶעĸԣ/൱

룺̷

14

Quality Risk Management/չ

6. INTEGRATION OF QUALITY RISK MANAGEMENT INTO INDUSTRY AND REGULATORY OPERATIONS չҵ缰ҩ Quality risk management is a process that supports science-based and practical decisions when integrated into quality systems (see Annex II). As outlined in the introduction, appropriate use of quality risk management does not obviate industrys obligation to comply with regulatory requirements. However, effective quality risk management can facilitate better and more informed decisions, can provide regulators with greater assurance of a companys ability to deal with potential risks, and might affect the extent and level of direct regulatory oversight. In addition, quality risk management can facilitate better use of resources by all parties.

չһ̣ϵϵʱ(¼ II)ֻ֧ڿѧʵľߡڼģǡչҵҩҪȻЧչԴʹú͸ԶľߣΪṩҵӦDZڷı֤ҿܻӰֱӼܵķΧˮƽ⣬չԴʹԴܱвŸõá

Training of both industry and regulatory personnel in quality risk management

processes provides for greater understanding of decision-making processes and builds confidence in quality risk management outcomes.

ҵԼҩԱչѵԸõ˽߹̣ҶչĽġ

Quality risk management should be integrated into existing operations and

documented appropriately. Annex II provides examples of situations in which the use of the quality risk management process might provide information that could then be used in a variety of pharmaceutical operations. These examples are provided for

illustrative purposes only and should not be considered a definitive or exhaustive list. These examples are not intended to create any new expectations beyond the requirements laid out in the current regulations.

չӦеӦļϵͳǡϡ¼ II ṩһЩõչ״ӣɶԲͬҩƷṩϢṩЩֻdz˵Ŀģ䲻ӦñΪһȨԵĻ꾡бҲûͼκµijԽǰļгҪ Examples for industry and regulatory operations (see Annex II): ҵҩ(¼ II) ? Quality management.

Examples for industry operations and activities (see Annex II): ҵ(¼ II) ? Development;

? Facility, equipment and utilities; ʩ豸빫ʩ

룺̷

15

Quality Risk Management/չ

? Materials management; Ϲ ? Production;

? Laboratory control and stability testing; ʵƺȶ飻 ? Packaging and labeling.װǩ Examples for regulatory operations (see Annex II): ҩ(¼ II)

? Inspection and assessment activities. 

While regulatory decisions will continue to be taken on a regional basis, a common understanding and application of quality risk management principles could facilitate mutual confidence and promote more consistent decisions among regulators on the basis of the same information. This collaboration could be important in the development of policies and guidelines that integrate and support quality risk management practices.

ҩ߽ijӦʱչԭһ˽ӦÿͬϢϴٽ֮໥IJҴʹһµľߡϺ֧չʵߺָϵĿdzҪ 7. DEFINITIONS Decision Maker(s): ߣ

Person(s) with the competence and authority to make appropriate and timely quality risk management decisions.

ȨǡIJʱվߵˡ Detectability: ɼԣ

The ability to discover or determine the existence, presence, or fact of a hazard. ֻȷΣմڣֻʵ Harm: ˺

Damage to health, including the damage that can occur from loss of product quality or availability.

Խ𺦣ڲƷЧʧ𺦡 Hazard: Σգ

The potential source of harm (ISO/IEC Guide 51). DZڵ˺Դ(ISO/IEC ָ 51)

룺̷

16

  • ղ
  • Υٱ
  • Ȩ
ĵ10.00 Ԫ VIP
ߣ...

92ƪĵ

ĵ飺

Quality Risk Management/չ authorities, communication concerning quality risk management decisions might be effected through existing channels as specified in regulations and guidances. չͨھߺԱ֮йطպͷչϢ֮κηչ̽׶νйͨ(ͼ 1 ĵ㻮߼ͷ)չ̵/ӦʵĹͨʹ浵(ͼ 1 ʵ߼ͷ)ͨпܰЩط磬ҩҵ硢ҵ뻼ߡһ˾ҵҩڲȡϢӦյĴԡʡʽʡԡɽԡơ

οͿͨغɸƺŰ棩
ƪ
ʱؼۣ10 Ԫ/ ԭ:20Ԫ
VIP
ؼۣ29 Ԫ/ ԭ:99Ԫ
0.3 Ԫ/ ÿ150
ȫվɸ
VIP
ؼۣ29 Ԫ/ ԭ:99Ԫ
0.3 Ԫ/ ÿ150
ȫվɸ
עĵпܡֻĿ¼ݲȫ֮ǰעѸ޷ػ⣬ϵЭ㴦
΢ţfanwen365 QQ370150219
Copyright © ⺣ All Rights Reserved. ICP16052595-3 վͼ ͷQQ370150219 䣺370150219@qq.com